2. Search Result
Search Result
Results for "

FZD7

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

4

Peptides

1

Inhibitory Antibodies

1

Recombinant Proteins

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1454
    Fz7-21
    3 Publications Verification

    Ac-LPSDDLEFWCHVMY-NH2

    		 Wnt Cancer
    Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids .
    Fz7-21
  • HY-P1454A
    Fz7-21 TFA
    3 Publications Verification

    Ac-LPSDDLEFWCHVMY-NH2 TFA

    		 Wnt Cancer
    Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids .
    Fz7-21 TFA
  • HY-156095
    F7H
    1 Publications Verification

    		 Wnt Cancer
    F7H is a Frizzled receptor FZD7 antagonist (IC50: 1.25 μM). Frizzled receptors (FZDs) influence Wnt signaling, mediating embryonic development and tissue homeostasis. F7H is a potent ligand for the FZD7 transmembrane domain (TMD) .
    F7H
  • HY-117002
    SRI 37892

    		Wnt Cancer
    SRI 37892 is a small molecule compound inhibitor of Frizzled protein 7 (Fzd7) with inhibitory activity against cancer cell proliferation (IC50=2μM). SRI 37892 significantly blocks Wnt/Fzd7 signaling. SRI 3789 can be used in the research of developing cancer therapeutic agents [1].
    SRI 37892
  • HY-P1454B
    Fz7-21S

    		Wnt Cancer
    Fz7-21S is a negative control of Fz7-21. Fz7-21 is a potent peptide antagonist of FZD7 receptors .
    Fz7-21S
  • HY-P10204
    FZD7 antagonist 1

    		Wnt Cancer
    FZD7 antagonist 1 (peptide 34) is a dFz7-21 analogue. FZD7 antagonist 1 is an FZD7 antagonist that inhibits the wnt3a with IC50 value of 9.2 nM. FZD7 antagonist 1 blocks TcdB−FZD interaction via targeting FZD receptors .
    FZD7 antagonist 1
  • HY-RS17191
    Fzd7 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA)
    Fzd7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fzd7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Fzd7 Mouse Pre-designed siRNA Set A
    Fzd7 Mouse Pre-designed siRNA Set A
  • HY-RS05183
    FZD7 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    FZD7 Human Pre-designed siRNA Set A contains three designed siRNAs for FZD7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FZD7 Human Pre-designed siRNA Set A
    FZD7 Human Pre-designed siRNA Set A
  • HY-P990418
    Anti-FZD7 Antibody

    		Smo Inflammation/Immunology
    The Anti-FZD7 Antibody is a human-derived antibody expressed in CHO, targeting FZD7. The Anti-FZD7 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FZD7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-FZD7 Antibody